Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Inhaled corticosteroid (ICS) / long-acting beta2-adrenergic agonist (LABA) combination

Fluticasone Furoate / Vilanterol

Breo Ellipta

Dosage form
Tablet
Available strengths
100 mcg/25 mcg, 200 mcg/25 mcg (fluticasone furoate/vilanterol per inhalation)
Drug class
Inhaled corticosteroid (ICS) / long-acting beta2-adrenergic agonist (LABA) combination
Common brand
Breo Ellipta

Clinical overview. Fluticasone furoate/vilanterol (Breo Ellipta) is a once-daily inhaled combination of a corticosteroid and a long-acting bronchodilator used for maintenance treatment of COPD and asthma. It is not a rescue inhaler and should be used regularly, with a fast-acting bronchodilator kept on hand for sudden symptoms. Common effects include headache, nasopharyngitis, and oral thrush, while rare but serious risks include pneumonia and cardiovascular effects.

Indication

Common therapeutic uses

  • Fluticasone furoate/vilanterol 100/25 mcg is used for the once-daily maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and to reduce COPD exacerbations in patients with a history of exacerbations.
  • Fluticasone furoate/vilanterol 100/25 mcg and 200/25 mcg are used for the once-daily maintenance treatment of asthma in patients 18 years and older whose disease is not adequately controlled on an inhaled corticosteroid alone or whose severity warrants combined ICS/LABA therapy.
  • It is not intended to relieve sudden asthma or COPD symptoms and must not replace a fast-acting rescue inhaler.

Pregnancy

Risk assessment and monitoring considerations

  • Fluticasone furoate/vilanterol has not been specifically studied in pregnant women, and it should be used during pregnancy only if the expected benefit justifies the potential risk to the fetus.
  • Beta2-agonists can potentially interfere with uterine contractions, so use during labour should only occur if the anticipated benefit outweighs the risk.
  • Women who become pregnant while using fluticasone furoate/vilanterol should contact their physician.

Breastfeeding

Infant exposure considerations

  • It is not known whether fluticasone furoate or vilanterol pass into human breast milk, though related corticosteroids and beta2-agonists have been detected in milk.
  • Breastfeeding women should only use fluticasone furoate/vilanterol if the expected benefit to the mother is greater than any possible risk to the infant.

Geriatrics

Dosing and tolerability considerations

  • No dose adjustment of fluticasone furoate/vilanterol is required in patients 65 years of age and older, though some older individuals may be more sensitive to its effects.

Pediatrics

Use in children and adolescents

  • The safety and effectiveness of fluticasone furoate/vilanterol in patients younger than 18 years of age have not been established, and it is not indicated in this age group.

Dosage & Administration

Practical dosing and administration

  • For COPD, the recommended and maximum dose is one inhalation of fluticasone furoate/vilanterol 100/25 mcg once daily; the 200/25 mcg strength is not indicated for COPD.
  • For asthma, the starting strength depends on prior therapy: patients previously on low- to mid-dose inhaled corticosteroid treatment typically start on 100/25 mcg once daily, while those on mid- to high-dose therapy typically start on 200/25 mcg once daily; the maximum dose is 200/25 mcg once daily.
  • Patients with moderate to severe liver impairment should be limited to the 100/25 mcg strength because fluticasone furoate exposure can increase up to three-fold; no dose adjustment is needed for mild hepatic impairment.
  • No dose adjustment is required for renal impairment.
  • If a dose is missed, the patient should take the next dose at the regular scheduled time and should not double up.
  • It should be taken once daily, at the same time every day, by oral inhalation only, and never more than once every 24 hours.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Overdose signs relate mainly to the vilanterol component and resemble excessive beta-adrenergic stimulation: chest pain (angina), fast heart rate up to 200 beats per minute, irregular heartbeat, high or low blood pressure, nervousness, tremor, headache, seizures, muscle cramps, dry mouth, nausea, dizziness, fatigue, insomnia, high blood sugar, and low blood potassium.
  • Cardiac arrest and death have been associated with overdose of inhaled sympathomimetic medicines such as vilanterol.
  • Chronic overdose of the fluticasone furoate component may cause signs of excess corticosteroid activity (hypercorticism), though acute toxic corticosteroid effects from a single overdose are unlikely given fluticasone furoate's low systemic absorption.
  • Management involves stopping fluticasone furoate/vilanterol, giving supportive and symptomatic care, and considering cardiac/ECG monitoring; a cardioselective beta-blocker may be used cautiously, since it can worsen bronchospasm.

Common side effects

Frequently reported tolerability concerns

  • Nasopharyngitis (common cold-type symptoms) may occur.
  • Upper respiratory tract infection may occur.
  • Oral or oropharyngeal thrush (candidiasis) may occur.
  • Sinusitis may occur.
  • Bronchitis may occur.
  • Pharyngitis may occur.
  • Headache may occur.
  • Back pain may occur.
  • Cough may occur.
  • Nausea may occur.
  • Fever may occur.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Pneumonia has occurred more often in COPD patients using fluticasone furoate/vilanterol, including cases requiring hospitalization and, rarely, fatal cases.
  • Increased risk of bone fracture has been observed in COPD patients, generally trauma-related.
  • Serious asthma-related events, including hospitalization and death, are a recognized risk of LABA medicines; fluticasone furoate/vilanterol combines the LABA with an inhaled corticosteroid, which mitigates but does not eliminate this risk.
  • Cardiovascular effects such as rapid or irregular heartbeat, palpitations, and changes in blood pressure may occur.
  • Paradoxical bronchospasm, a sudden worsening of wheezing right after inhalation, may occur.
  • Signs of adrenal suppression or Cushingoid features (rounded face, weight gain, thinning skin) may develop with prolonged use.
  • Serious allergic reactions, including anaphylaxis, throat and tongue swelling, and hives, may occur.
  • Vision problems including glaucoma, increased eye pressure, cataracts, or central serous chorioretinopathy may develop with long-term use.
  • Reduced growth velocity may occur in adolescents, though the drug is not approved under 18.
  • Low blood potassium and high blood sugar may occur.
  • Seek urgent medical attention for chest pain, a very fast or irregular heartbeat, fainting, severe shortness of breath, or facial/throat swelling.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with severe cardiovascular disease, coronary insufficiency, cardiac arrhythmias, or hypertension.
  • Use with caution in patients with a history of QT interval prolongation or in those taking other medicines that prolong the QT interval.
  • Use with caution in patients being transitioned from oral corticosteroids, since deaths from adrenal insufficiency have occurred during such transfers.
  • Use with caution in patients with major risk factors for reduced bone mineral density.
  • Use with caution in patients with diabetes, since blood glucose should be monitored more closely.
  • Use with caution in patients predisposed to low blood potassium.
  • Use with caution in patients with convulsive disorders or an overactive thyroid (thyrotoxicosis).
  • Use with caution in patients with active or past tuberculosis, or chronic fungal, bacterial, viral, or parasitic infections.
  • Use with caution in patients with cataracts, glaucoma, or a history of increased eye pressure.
  • Use with caution in COPD patients who currently smoke, have a low body mass index, or have severe airflow limitation, since these raise pneumonia risk.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to fluticasone furoate, vilanterol, or any ingredient of the formulation.
  • Contraindicated in patients with severe hypersensitivity to milk proteins, since the powder formulation contains lactose.
  • Contraindicated as primary treatment for status asthmaticus or other acute asthma episodes.

Drug interactions

Clinically relevant combinations

  • Strong CYP3A4 inhibitors such as ketoconazole, ritonavir, clarithromycin, itraconazole, and similar drugs can increase fluticasone furoate and vilanterol levels and should generally be avoided or used with monitoring for corticosteroid and cardiovascular side effects.
  • Beta-blockers, including those in eye drops, may weaken the bronchodilating effect of fluticasone furoate/vilanterol; if a beta-blocker is unavoidable, a cardioselective one should be used cautiously.
  • Monoamine oxidase inhibitors, tricyclic antidepressants, and other drugs that prolong the QT interval may increase the risk of ventricular arrhythmia when combined with fluticasone furoate/vilanterol.
  • Other sympathomimetic medicines can add to fluticasone furoate/vilanterol's cardiovascular effects and should not be combined.
  • Xanthine derivatives (such as theophylline), oral corticosteroids, and non-potassium-sparing diuretics can increase the risk of low blood potassium when combined with fluticasone furoate/vilanterol.
  • No clinically significant interaction has been found between fluticasone furoate/vilanterol and acetylsalicylic acid, though caution is still advised in patients prone to reduced blood clotting.

Food interactions

Meal-related administration

  • Fluticasone furoate/vilanterol is an inhaled medicine, so it can be used with or without food; food has no meaningful effect on how it works.

Time of administration

Practical scheduling

  • Take fluticasone furoate/vilanterol once daily at the same time each day, morning or evening, regardless of meals, since food timing does not affect this inhaled medicine.

Storage

Product handling

  • Store fluticasone furoate/vilanterol below 25°C, in a dry place away from direct heat and sunlight, out of the sight and reach of children.
  • If stored in a refrigerator, allow the inhaler to return to room temperature for at least an hour before use.
  • Discard the inhaler six weeks after removal from its protective tray, or when the dose counter reads zero, whichever comes first.

Patient take-away

Key counselling points for a quick closing summary

  • Fluticasone furoate/vilanterol is a once-daily combination inhaler that controls COPD or asthma symptoms over time; it is not a rescue inhaler and will not relieve sudden breathing difficulty.
  • Always keep a fast-acting rescue inhaler on hand for sudden symptoms.
  • Rinse the mouth with water and spit it out after each dose to lower the risk of oral thrush.
  • Continue using it regularly, even when feeling well, and contact a healthcare professional before stopping.

References

Source material and product information

  1. Health Canada Product Monograph — Fluticasone Furoate / Vilanterol

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.